Showing 8471-8480 of 8647 results for "".
- Glaucoma Research Foundation Speeds Search for a Curehttps://modernod.com/news/glaucoma-research-foundation-speeds-search-for-a-cure/2480187/Glaucoma Research Foundation has announced the celebration of its 40th anniversary year, the board approval of its new strategic plan, and an expanded capital campaign designed to accelerate research towards a cure. Commemorated at an April 24 annual dinner at the War Memorial in San F
- New Novartis Phase 3 Data for Brolucizumab Demonstrate Reliability of 12-Week Treatment Intervalhttps://modernod.com/news/new-novartis-phase-3-data-for-brolucizumab-demonstrate-reliability-of-12-week-treatment-interval/2480190/Novartis announced new positive brolucizumab (RTH258) data in neovascular age-related macular degeneration (AMD) from a prespecified secondary analysis of the phase 3 HAWK and HARRIER trials. The findings showed that patients assessed as appropriate for a 12-week treatment frequency during
- Lighthouse Guild Behavioral Programs Focus on the Psychological Impact of Vision Loss, Traumatic Brain Injury and Other Disabilitieshttps://modernod.com/news/lighthouse-guild-behavioral-programs-focus-on-the-psychological-impact-of-vision-loss-traumatic-brain-injury-and-other-disabilities/2480194/For the millions of people who have vision loss, have suffered a traumatic brain injury (TBI), or have developed other physical disabilities due to accident or illness, the psychological impact can be devastating. To meet the needs of these patients, Lighthouse Guild, the leading not-for-profit v
- Hill-Rom Enhances Spot Vision Screener to Serve Senior Populationhttps://modernod.com/news/hill-rom-enhances-spot-vision-screener-to-serve-senior-population/2480205/Hill-Rom announced new enhancements to its Welch Allyn Spot Vision Screener, enabling the device to quickly and effectively screen for vision issues in adult patients with pupil sizes as small as 3 mm, according to a company news release. Spot Vision Screener is a handheld, portable device
- First Clinical Uses of Medineering Robotic Endoscopyhttps://modernod.com/news/first-clinical-uses-of-medineering-robotic-endoscopy/2480207/Medineering, a Munich, Germany-based surgical robotics company, announced the first clinical uses of its robotic Medineering Robotic Endoscopy. After having received the CE approval for the Endoscope Robot in February, various clinical uses in university hospitals across Germany (Tübingen, Ulm, R
- Market Scope: China’s Ophthalmic Market to grow 11.3% to $4.5 Billion in 2023https://modernod.com/news/market-scope-chinas-ophthalmic-market-to-grow-11-3-to-4-5-billion-in-2023/2480211/Market Scope forecasts that China’s $2.6 billion ophthalmic market will grow at a compound annual rate of 11.3 percent over the next 5 years to $4.5 billion in 2023. China has tremendous unmet need for ophthalmic care. The country is home to approximately one-third of the world’s blind peo
- New CSP Report for the Oculus Pentacamhttps://modernod.com/news/new-csp-report-for-the-oculus-pentacam/2480216/Oculus announced the release of the new CSP Report, allowing the Pentacam to measures sagittal height, a parameter needed for scleral lens fitting. With the upgrade, 250 Scheimpflug images covering a diameter of up to
- Congressional Briefing Discussing Safety of Contact Lenses as Regulated Medical Devices to be Held Tomorrowhttps://modernod.com/news/congressional-briefing-discussing-safety-of-contact-lenses-as-regulated-medical-devices-to-be-held-tomorrow/2480218/The Health Care Alliance for Patient Safety will hold a congressional briefing tomorrow, Tuesday, April 24, 2018, from noon-1 pm in The Rayburn House Office Building, Room 2247, in Washington DC, to discuss the importance of protecting the safety of patients who use contact lenses, which are regu
- Two New Drug Classes Tied to Better Survival in Type 2 Diabeteshttps://modernod.com/news/two-new-drug-classes-tied-to-better-survival-in-type-2-diabetes/2480222/Patients with type 2 diabetes who did not achieve adequate glycemic control with metformin had improved survival during follow-up if they received add-on therapy with a sodium-glucose cotransporter 2 (SGLT-2) inhibitor or a glucagon-like peptide 1 (GLP-1) agonist rather than a dipeptidyl peptidas
- TFOS Recognizes the Bioprotectant Properties of Trehalose, a Component of Thealoz Duo, in the Treatment of Dry Eyehttps://modernod.com/news/tfos-recognizes-the-bioprotectant-properties-of-trehalose-a-component-of-thealoz-duo-in-the-treatment-of-dry-eye/2480223/The TFOS international Dry Eye WorkShop II (TFOS DEWS II), whose report has been published in the July 2017 issue of the Ocular Surface journal, acknowledged that trehalose is an effective ingredient in association with hyaluronic acid for the tre